Mark Kay MD, PhD

Mark Kay, MD, PhD is a distinguished researcher and professor with extensive experience in gene therapy and genetics. Here are the key details about his background and current roles:

Professional Experience

Mark Kay currently holds several prominent positions:

• Founder, SAB and BOD at LogicBio Therapeutics since November 20151
• Scientific Founder and SAB member at Voyager Therapeutics since January 20141
• Professor at Stanford University School of Medicine since March 19981

Academic Background

Dr. Kay has a strong educational foundation:

• BS in Physical Sciences from Michigan State University (1976-1980)1
• MD and PhD in Developmental Genetics and Medicine from Case Western Reserve University School of Medicine (1980-1987)1
• Completed training in Pediatrics, Medical Genetics, and Biochemical Genetics at Baylor College of Medicine (1987-1993)1

Research and Contributions

Dr. Kay is renowned for his work in gene therapy:

• He leads research in gene transfer technologies and hepatic gene therapy for genetic and acquired diseases5
• His lab focuses on developing new vector systems and delivery methods for gene therapy5
• He has made significant contributions to adeno-associated virus (AAV) biology and vector development4

Professional Recognition

Dr. Kay has received numerous accolades:

• Elected to the National Academy of Inventors in 20202
• Received the Outstanding Investigator Award from the American Society of Gene and Cell Therapy in 20133
• Served as President of the American Society of Gene Therapy in 2005-20062
• Elected to the American Academy of Pediatrics in 20102

Dr. Kay's extensive experience and contributions have established him as a leading figure in the field of gene therapy and genetic research.